Odyssey Therapeutics, Inc.
ODTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001882782
No open-market purchases or sales by Odyssey Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $652.9M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Odyssey Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Odyssey Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Coulter James G | Other: Former 10% Owner | 3,690,146Indirect | May 13, 2026 | 1 |
| Winkelried Jon | Other: Former 10% Owner | 3,690,146Indirect | May 13, 2026 | 1 |
| TPG GP A, LLC | Other: Former 10% Owner | 3,690,146Indirect | May 13, 2026 | 1 |
| Dimension Capital II, L.P. | Director | 3,333,516 | May 12, 2026 | 1 |
| George Simeon | 10% Owner | 1,014,851Indirect | May 11, 2026 | 1 |
| Sr One Capital Management, LLC | 10% Owner | 1,014,851Indirect | May 11, 2026 | 1 |
| Smith Ian F | Director | – | May 11, 2026 | 1 |
| Leiden Jeffrey M | Director | 31,644Indirect | May 11, 2026 | 1 |
| Walbert Timothy P | Director | – | May 11, 2026 | 1 |
| Tatsis Ourania | Director | – | May 11, 2026 | 1 |
| Odegard Valerie | Director | – | May 11, 2026 | 1 |
| Haas Jason | Chief Financial Officer | 62,908 | May 11, 2026 | 1 |
| Chu Shelley | Director | 11,111 | May 11, 2026 | 1 |
| Todd Collin M | See Remarks | – | May 11, 2026 | 1 |
| Glick Gary D | See Remarks | 415,973 | May 11, 2026 | 1 |
| Dales Natalie | See Remarks | – | May 11, 2026 | 1 |
| Opipari Anthony W. | See Remarks | 7,502 | May 11, 2026 | 1 |
| Li Nan (LN) | Director | 3,333,516Indirect | May 11, 2026 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 (view filing)5:10 PM ET | May 11 | 2 days | Coulter James G and 2 othersOther: Former 10% Owner | PPurchase | +1.39M | $18.00 | +$25.0M | +60.4%3.69M after | |
| May 12, 2026 (view filing) | May 8 | 4 days | Dimension Capital II, L.P.Director | PPurchase | +1.11M | $18.00 | +$20.0M | +50.0%3.33M after | |
| May 11, 2026 (view filing)9:11 PM ET | May 11 | Same day | George Simeon and 1 other10% Owner | SSale | −1.78K | $18.00 | −$32.0K | −0.2%814.9K after | 3 lots |
| May 11, 2026 (view filing)9:11 PM ET | May 11 | Same day | George Simeon and 1 other10% Owner | PPurchase | +555.6K | $18.00 | +$10.0M | +121.0%1.01M after | 3 lots |
| May 11, 2026 (view filing) | May 8 | 3 days | Leiden Jeffrey MDirector | PPurchase | +5.00K | $20.00 | +$100.0K | +1.9%270.2K after | |
| May 11, 2026 (view filing) | May 8 | 3 days | Haas JasonChief Financial Officer | PPurchase | +1.00K | $20.00 | +$20.0K | +1.6%62.9K after | |
| May 11, 2026 (view filing) | May 11 | Same day | Li Nan (LN)Director | PPurchase | +1.11M | $18.00 | +$20.0M | +50.0%3.33M after | |
| May 11, 2026 (view filing) | May 11 | Same day | Chu ShelleyDirector | PPurchase | +11.1K | $18.00 | +$200.0K | New position11.1K after |